Medications for Dystrophic Epidermolysis Bullosa
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Dystrophic Epidermolysis Bullosa.
Found 2 Approved Drugs for Dystrophic Epidermolysis Bullosa
Vyjuvek
Generic Name
Vyjuvek
Vyjuvek
Generic Name
Vyjuvek
Form: Kit
FDA approval date: May 19, 2023
VYJUVEK is indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. VYJUVEK is a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
Zevaskyn
Generic Name
Prademagene Zamikeracel
Zevaskyn
Generic Name
Prademagene Zamikeracel
Form: Cellular
Method of administration: Topical
FDA approval date: April 13, 2025
ZEVASKYN is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ( 1 )
Showing 1-2 of 2
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances